Ameriprise
CARM

Ameriprise’s Carisma Therapeutics CARM Stock Holding History

Ameriprise’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-533
Closed -$6K – 3950
2022
Q4 		$6K Sell
533
-10
-2% -$105 ﹤0.01% 3942
2022
Q3 		$5K Buy
+543
New +$7.4K ﹤0.01% 3944
2022
Q1 		– Sell
-685
Closed -$11K – 3950
2021
Q4 		$11K Sell
685
-8,892
-93% -$179K ﹤0.01% 3936
2021
Q3 		$152K Buy
9,577
+643
+7% +$30.9K ﹤0.01% 3738
2021
Q2 		$823K Buy
8,934
+6,454
+260% +$412K ﹤0.01% 3300
2021
Q1 		$129K Buy
2,480
+1,674
+208% +$79K ﹤0.01% 3751
2020
Q4 		$22K Buy
+806
New +$20.4K ﹤0.01% 3743

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Deuterium Capital Management Clearwater, Florida $86M AUM 87.31% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's CARM Position: Q1 2023 in Review

Ameriprise sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 533 shares — an estimated $6K sold.

Ameriprise first reported a position in CARM in Q4 2020 and held it in 7 quarters. The position peaked at $823K in Q2 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

  • Ameriprise reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ameriprise sold 533 Carisma Therapeutics shares in Q1 2023, an estimated $6K.
  • Ameriprise first reported a position in Carisma Therapeutics in Q4 2020 and held it in 7 quarters.
  • Ameriprise's Carisma Therapeutics position peaked at $823K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on Ameriprise's 13F filing for Q1 2023, filed 15 May 2023.